Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing);
Department of Breast Oncology;
Peking University Cancer Hospital&Institute;
Beijing 100142;
China;
Department of Gastrointestinal Oncology;
the Fifth Medical Center of Chinese PLA General Hospital;
Beijing 100071;
China;
Department of Gynecological Oncology;
Tianjin Medical University Cancer Institute&Hospital;
Tianjin 300060;
China;
Departnient of Gynecologic Oncology;
Sun Yat-sen University Cancer Centre;
Guangzhou 510060;
China;
The Comprehensive Cancer Center of Drum Tower Hospital;
the Affiliated Drum Tower Hospital of Nanjing University Medical School;
Nanjing 210008;
China;
Department of Clinical Medicine-Oncology;
Jiangsu Hengrui Medicine Co.;
Ltd.;
Shanghai 201203;
China;
Department of Medicine;
University of California San Francisco Comprehensive Cancer Center;
San Francisco 94127;
USA;
State Key Laboratory of Drug Research;
Shanghai Institute of Materia Medica;
Chinese Academy of Sciences;
Shanghai 201203;
China;
PhaseⅠ; PARP inhibitor(fluzoparib); solid tumor; pharmacokinetics; safety; antitumor activity;